Clinical Trials Browser

Interventional × Neoplasm Metastasis × Lenalidomide × Clear all

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase 1/2 Terminated

83 enrolled 31 charts

Neoplasm Metastasis

NCT00057616 2019-11-08

Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

Phase 3 Completed

Melanoma, Neoplasm Metastasis

NCT01342172 2019-04-23

Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

Phase 1/2 Terminated

9 enrolled 9 charts

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Phase 1 Completed

BreastCNSDermatologicGastrointestinalGenitourinaryOther hematologic neoplasmPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT00055562 2005-06-24

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Phase 2/3 Completed

Melanoma, Neoplasm Metastasis